$0.58
0.17% day before yesterday
Nasdaq, Dec 27, 10:11 pm CET
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

FibroGen, Inc. Stock price

$0.58
+0.19 49.10% 1M
-0.45 43.69% 6M
-0.31 34.56% YTD
-0.23 28.32% 1Y
-14.31 96.10% 3Y
-44.31 98.71% 5Y
-26.92 97.89% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.17%
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

Key metrics

Market capitalization $58.45m
Enterprise Value $62.40m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.35
P/S ratio (TTM) P/S ratio 0.32
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 16.15%
Revenue (TTM) Revenue $180.01m
EBIT (operating result TTM) EBIT $-94.40m
Free Cash Flow (TTM) Free Cash Flow $-126.23m
Cash position $131.00m
EPS (TTM) EPS $-1.23
P/E forward negative
P/S forward 0.33
EV/Sales forward 0.35
Short interest 5.07%
Show more

Is FibroGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

FibroGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a FibroGen, Inc. forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a FibroGen, Inc. forecast:

Buy
50%
Hold
50%

Financial data from FibroGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
180 180
16% 16%
100%
- Direct Costs 42 42
127% 127%
23%
138 138
1% 1%
77%
- Selling and Administrative Expenses 83 83
28% 28%
46%
- Research and Development Expense 146 146
50% 50%
81%
-90 -90
67% 67%
-50%
- Depreciation and Amortization 4.22 4.22
61% 61%
2%
EBIT (Operating Income) EBIT -94 -94
66% 66%
-52%
Net Profit -122 -122
59% 59%
-68%

In millions USD.

Don't miss a Thing! We will send you all news about FibroGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

FibroGen, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024.
Neutral
Seeking Alpha
about 2 months ago
FibroGen, Inc. (NASDAQ:FGEN ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A & IR Thane Wettig - CEO Juan Graham - CFO Conference Call Participants Andy Hsieh - William Blair Operator Good day and welcome to the FibroGen Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
Neutral
GlobeNewsWire
about 2 months ago
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company's recent developments.
More FibroGen, Inc. News

Company Profile

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Head office United States
CEO Thane Wettig
Employees 486
Founded 1993
Website www.fibrogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today